Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other financing activities (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Other financing activities over the past 14 years, most recently at $107000.0 for Q2 2024.

  • Quarterly results put Other financing activities at $107000.0 for Q2 2024, down 95.51% from a year ago — trailing twelve months through May 2025 was $6.2 million (changed 0.0% YoY), and the annual figure for FY2025 was $435000.0, up 88.31%.
  • Other financing activities for Q2 2024 was $107000.0 at Lifecore Biomedical, Inc. \De\, down from $2.4 million in the prior quarter.
  • Over the last five years, Other financing activities for LFCR hit a ceiling of $8.4 million in Q1 2021 and a floor of $37000.0 in Q1 2022.
  • Median Other financing activities over the past 5 years was $725000.0 (2020), compared with a mean of $1.7 million.
  • Biggest five-year swings in Other financing activities: crashed 99.56% in 2022 and later soared 9816.22% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Other financing activities stood at $725000.0 in 2020, then crashed by 81.79% to $132000.0 in 2021, then soared by 393.94% to $652000.0 in 2022, then soared by 265.18% to $2.4 million in 2023, then tumbled by 95.51% to $107000.0 in 2024.
  • The last three reported values for Other financing activities were $107000.0 (Q2 2024), $2.4 million (Q2 2023), and $3.7 million (Q1 2023) per Business Quant data.